Regardless, the GRK1·amlexanox structure will serve as a useful platform to begin rational design of amlexanox-based therapeutics for the treatment of either cardiac hypertrophy (GRK5) or, by extension, diabetes (IKKε). This evidence concerns the gene IKBKE and cardiac hypertrophy.